Loading…
APO-LORATADINE is a brand name for Loratadine, supplied as a tablet. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: AND CLINICAL USE ......................................................................................................... 3 CONTRAINDICATIONS ............................................................................................................................ 3 WARNINGS AND PRECAUTIONS…
Verbatim from this product's HC label. Tap a section to expand.
Hepatic/Biliary/Pancreatic In patients with chronic alcoholic liver disease, the AUC and peak plasma levels (Cmax) of loratadine were double while the pharmacokinetic profile of the active metabolite was not significantly changed from that in patients with normal liver function.
The elimination half-lives for loratadine and its active metabolite were 24 hours and 37 hours, respectively, and increased with increasing severity of liver disease. Dosing adjustment is therefore recommended in patients with severe liver disease.
Patients with severe liver impairment should be administered a lower initial dose because they may have reduced clearance of loratadine (See DOSAGE AND ADMINISTRATION, Dosing Considerations). Renal In patients with chronic renal impairment, both the AUC and peak plasma levels (Cmax) increased for loratadine and its metabolite as compared to the AUCs and peak plasma levels (Cmax) of patients with normal renal function.
The mean elimination half-lives of loratadine and its metabolite were not significantly different from that observed in normal subjects. Haemodialysis does not have an effect on the pharmacokinetics of loratadine or its active metabolite in subjects with chronic renal impairment.
Therefore, no dosage adjustments are required in patients with renal insufficiency. In the case of severe renal insufficiency, loratadine should be used with caution.
Special Populations Pregnant Women:
The safe use of loratadine during pregnancy has not been established and is therefore not recommended.
Nursing Women:
The safe use of loratadine during lactation has not been established and is therefore not recommended. (See DETAILED PHARMACOLOGY / Human Pharmacology for information on secretion into breast milk).
Pediatrics (2 to 12 years of age):
The safety and efficacy of loratadine in children younger than 2 years of age have not been established. Long-term safety and efficacy of loratadine in children between the ages of 2 and 12 has not been demonstrated. Therefore, it is desirable that loratadine not be administered to children between the ages of 2 and 12 for longer than 14 days, unless recommended by a physician.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Loratadine in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
ADVERSE REACTIONS Adverse Drug Reaction Overview Adverse experiences reported with loratadine in adults during clinical trials were mild and consisted of fatigue, headache, dry mouth, sedation, gastrointestinal disorders such as nausea, gastritis, and also allergic symptoms like rash.
Nervousness and hyperkinesia were among the reported adverse experiences in pediatric patients. Gastrointestinal adverse reactions reported during pediatric trials may have been slightly more frequent in the younger patients (less than or equal to 30 kg).
Page 5 of 20 During the marketing of loratadine, alopecia, anaphylaxis, abnormal hepatic function, dizziness, palpitations and tachycardia have been reported rarely. Clinical Trial Adverse Drug Reactions Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug.
Adverse drug reaction information, from clinical trials is useful for identifying drug-related adverse events and for approximating rates. Adverse experiences reported with loratadine conventional tablets in adults during the clinical trials were mild and consisted of fatigue, headache, dry mouth, sedation, gastrointestinal disorders such as nausea, gastritis, and also allergic symptoms like rash.
01) from clemastine. Less Common Clinical Trial Adverse Drug- Reactions (<1%) In addition to those listed in Table 1, the following were reported less frequently (less than 1%): appetite increased, coughing, dizziness and palpitations.
Abnormal Hematologic and Clinical Chemistry Findings Not applicable Post-Market Adverse Drug Reactions During the marketing of loratadine, in addition to the adverse events reported during clinical trials, alopecia, anaphylaxis (including angioedema), abnormal hepatic function, dizziness, palpitations and tachycardia have been reported rarely.
Convulsions and seizures have been reported very rarely.
Table 1:
Loratadine Tablets, 10 mg Once Daily vs. Placebo and Comparatives Number (%) of Adult Patients Reporting Frequently Occurring (>2% of loratadine treated patients) Adverse Experiences in Adults Possibly or Probably Related to Treatment: Patients Treated with Loratadine, Placebo and Comparatives Loratadine 10 mg QD Placebo Clemastine 1 mg BID Terfenadine 60 mg BID Astemizole 10 mg OD n = 1241 n = 1652 n = 687 n = 506 n = 342 Adverse Experience Fatigue 54(4) 62(4) 62(9) 17(3) 22(6) Headache 97(8) 104(6) 32(5) 40(8) 26(7) Dry Mouth 49(4) 32(2) 22(3) 15(3) 2(1) Dryness in Nose 9(<1) - 6(<1) 3(<1) - Sedation* 99(8) 101(6) 151(22) 41(8) 50(15) *Reported as somnolence, sleepiness, drowsiness, lethargy, slow or “drugged feeling” Page 6 of 20 DRUG INTERACTIONS Serious Drug Interactions None to report Overview When administered concomitantly with alcohol, loratadine has no potentiating effects as measured by psychomotor performance studies (see DETAILED PHARMACOLOGY / Human Pharmacology).
Drug-Drug Interactions Increases in plasma concentrations of loratadine have been reported after concomitant use with ketoconazole, erythromycin or cimetidine in controlled clinical trials, but without clinically significant changes (including electrocardiographic).
Other drugs known to inhibit hepatic metabolism should be coadministered with caution until definitive interaction studies can be completed. Drug-Food Interactions See ACTION AND CLINICAL PHARMACOLOGY / Pharmacokinetics / Absorption.
Drug-Herb Interactions Interactions with herbs have not been established. Drug-Laboratory Interactions Loratadine should be discontinued […]